Displaying 1 publication

Abstract:
Sort:
  1. Mac Guad, R., Zaharan, N.L., Wan Md Adnan, W.A.H., Gan, S.H., Chik, Z.,
    JUMMEC, 2019;22(1):20-26.
    MyJurnal
    Aim: A once-daily formulation of tacrolimus, Advagraf®, is increasingly being used in place of twice-daily
    tacrolimus, Prograf®, as a standard immunosuppressive agent for transplant patients. In this study, the
    clinical safety and efficacy of Advagraf® were compared with Prograf®, among multi-ethnic Malaysian renal
    transplanted population.

    Method: This retrospective study identified renal transplant patients who were converted from Prograf® to
    Advagraf® at the University Malaya Medical Centre (UMMC) (n=69). Clinical notes and laboratory records,
    including tacrolimus daily dose and trough levels, were obtained for one-year, pre-and post-conversion. Causality
    assessment of suspected adverse events were based on the WHO-Uppsala Monitoring Center criteria. Renal
    biopsy records were re-evaluated based on the updated Banff 2007 classification for biopsy-confirmed acute
    rejection (BPAR).

    Results: Following conversion to Advagraf®, the mean tacrolimus trough level and daily dose decreased
    significantly (p
Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links